Clinical Trials Browser

Phase 2 × Oligodendroglioma × tislelizumab × Clear all

NCT05512351 2022-09-27

Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNAlevel- Relapse and Clinical-relapse Oligodendroglioma

Phase 2 Recruiting

Oligodendroglioma